Ghana FDA reports GH¢70m surplus amid laboratory equipment concerns

Ghana’s Food and Drugs Authority (FDA) reported a GH¢70 million surplus for 2025, a 51 per cent increase from the GH¢46 million recorded in 2024. During the agency’s Annual Stakeholders’ Meeting in Accra, Deputy Director of Finance Samuel Adom-Siaw disclosed that total assets grew to GH¢358 million, while liabilities decreased to GH¢3.4 million.

Total revenue reached GH¢420 million, driven primarily by GH¢278 million in internally generated funds (IGF), which accounted for 66 per cent of the total. Despite this, the FDA faced a GH¢95 million shortfall against its projected IGF target, a gap attributed to exchange-rate fluctuations. The agency plans to address this by strengthening revenue mobilization and reviewing fee structures.

Operational challenges remain a priority, specifically the risks posed by ageing laboratory equipment and the circulation of illicit products. In terms of regulatory activity, the FDA processed 24,225 product applications, resulting in 20,205 approvals. The agency also conducted 15,457 facility inspections and examined 47,189 consignments at ports. Notably, locally manufactured products accounted for 62 per cent of registered regulated products, up from 33 per cent in 2024.